Regulation

Lawsuit against FDA on NMN ‘certainly being considered’, says NPA CEO

Lawsuit against FDA on NMN ‘certainly being considered’, says NPA CEO

By Stephen Daniells

The Natural Products Association is hoping the US Food & Drug Administration is responsive to its recent Citizen’s Petition on the status of NMN, but if it’s not then other options are being considered, Dr Daniel Fabricant, NPA’s CEO tells NutraIngredients-USA.

What to expect from the International Conference on the Science of Botanicals

Oxford ICSB: ‘You always learn something from this meeting’

By Stephen Daniells

From authentication and identification of botanicals to approached to establishing safety and efficacy, the 21st International Conference on the Science of Botanicals (ICSB) provides stakeholders in the botanicals space a unique opportunity to learn and...

Getty | Denia Fernandez

Expert opinion

ESSNA insights: CBD developments for the sports nutrition industry

By Nikki Hancocks

The number of sports and active nutrition companies investing in CBD has grown significantly in Europe over the last few years despite regulatory uncertainty, so what does this market hold for these brands? In this article, ESSNA’s Chair Dr Adam Carey,...

Steve Mister on FDA, MPL, CBD, and CRN at 50

Steve Mister on proposed FDA reorg, MPL, CBD, and CRN at 50

By Stephen Daniells

The first month of 2023 is over, and already there’s some big developments (or non-developments in the case of CBD) for the US dietary supplements industry. We caught up with Steve Mister, president and CEO of the Council for Responsible Nutrition, to...

What to expect from the new look NutraIngredients-USA!

Say hello to our new look!

You’re not wrong. The site does look different. Welcome to the new look NutraIngredients-USA!

5 take-aways we learned during our Business Leaders Forum

5 take-aways we learned during our Business Leaders Forum

By Stephen Daniells

From 2022 sales numbers to consumer enthusiasm remaining high, and from progress with equality and diversity in the industry to the growth in awareness around the importance of the microbiome for health, there were lots of talking points from our 3rd...

Getty Images / skynesher

Drumroll, please… waiting game continues to plague CBD industry

By Danielle Masterson

Rumors about a big FDA announcement began swirling earlier this week, with the industry bracing for a potential end to a five-year wait on the regulatory future of CBD. But, much like the last few years, CBD professionals were left waiting without answers,...

© vovashevchuk / Getty Image

State-led restrictive bills back to the fore for 2023

By Stephen Daniells

With bills in New Jersey, Massachusetts, and California already working through the State legislatures, the dietary supplements industry is bracing for another year of attempts to restrict access to products.

©Getty Images - David Trood

The hits keep coming on the CBD COVID claims jukebox

By Hank Schultz

Despite President Biden infamously declaring that the COVID-19 pandemic is over, there is no shortage of CBD companies claiming to cure or treat the disease, as a glance at the latest warning letters shows.

© OnickzArtworks / Getty Images

France to allow ‘probiotic’ on food supplements labels

By Stephen Daniells

France's General Directorate for Competition, Consumer Affairs and Fraud Prevention (DGCCRF), part of its Ministry of the Economy, has announced that the term “probiotic” will be allowed on the labels of food supplements in the country.

Getty images / skynesher

CBD in 2022: A year in review

By Danielle Masterson

We’re five years in, so what does the CBD industry look like now and what can we expect in 2023? We spoke with several CBD experts who walked us through the highs and lows of 2022.

Follow us

Products

View more

Webinars